Insomnia Treatment Guidelines

First-Line Treatment: CBT-I

The American Academy of Sleep Medicine recommends Cognitive Behavioral Therapy for Insomnia (CBT-I) as first-line treatment for all adults with chronic insomnia, with pharmacological therapy reserved as second-line treatment only when CBT-I alone is unsuccessful 1, 2
CBT-I has demonstrated superior long-term efficacy compared to pharmacological options and carries minimal risk of adverse effects 1
Key components of CBT-I include stimulus control, sleep restriction therapy, cognitive therapy to restructure maladaptive thoughts about sleep, sleep hygiene education, and relaxation techniques to reduce psychophysiological arousal 2, 3
Collection of sleep diary data before and during treatment is recommended to monitor progress 2

The American Academy of Sleep Medicine recommends using short/intermediate-acting benzodiazepine receptor agonists (BzRAs) at the lowest effective dose for the shortest period possible (4-5 weeks) 1
Options for BzRAs include zaleplon, zolpidem, eszopiclone, and temazepam, each with different half-lives and indications for sleep onset or maintenance issues 1, 3
Low-dose doxepin (3-6 mg) is particularly effective for sleep maintenance insomnia 4
Other sedating antidepressants that may be considered include trazodone and mirtazapine, with mirtazapine being beneficial for patients with comorbid depression and insomnia 4

Medication selection should be based on symptom pattern, patient's age and comorbidities, previous treatment response, risk of abuse/dependence, and cost and patient preference 3, 4
The FDA has approved pharmacologic therapy for short-term use only (4-5 weeks) 1
Potential adverse effects of BzRAs include residual sedation and daytime impairment, memory and performance impairment, falls and injuries, and behavioral abnormalities including "sleep driving" 1, 3
Benzodiazepines should be avoided in patients with a history of substance use due to high abuse potential 2
Antihistamine sleep aids and herbal substances such as valerian are not recommended due to lack of efficacy and safety data 4

Start with CBT-I as first-line treatment, implementing all components and continuing for at least 4-8 weeks to evaluate effectiveness 1, 2
If CBT-I is insufficient after adequate trial, consider pharmacological options based on symptom pattern and patient characteristics 1, 3, 4
When using medications, start with the lowest effective dose, limit duration to 4-5 weeks when possible, and continue incorporating behavioral techniques 1, 4
Monitor regularly for treatment response, adverse effects, and potential misuse 2